Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial-Reference-Cited by-同舟云学术

Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial

Published:2016-12 Issue:12 Volume:3 Page:e561-e568
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Gaur Aditya H,Kizito Hilda,Prasitsueubsai Wasana,Rakhmanina Natella,Rassool Mohammed,Chakraborty Rana,Batra Jagmohan,Kosalaraksa Pope,Luesomboon Wicharn,Porter Danielle,Shao Yongwu,Myers Michael,Ting Lillian,SenGupta Devi,Quirk Erin,Rhee Martin S

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference20 articles.

1. Centers for Disease Control and Prevention;HIV surveillance report,2014

2. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth;Reisner;Top HIV Med,2009

3. Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era;Sterrantino;Patient Prefer Adherence,2012

4. ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablets. US Prescribing Information. Gilead Sciences and Bristol-Myers Squibb. Foster City, CA, USA. June, 2008.

5. Gilead Sciences Inc. GENVOYA (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) tablets, for oral use. US Prescribing Information. Gilead Sciences and Bristol-Myers Squibb. Foster City, CA, USA. Initial approval November 5, 2015; revised March, 2016.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial;The Lancet Regional Health - Western Pacific;2024-08

2. Projected Life Expectancy for Adolescents With HIV in the US;JAMA Health Forum;2024-05-10

3. Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study;The Lancet HIV;2024-05

4. Health-Related Physical Fitness Evaluation in HIV-Diagnosed Children and Adolescents: A Scoping Review;International Journal of Environmental Research and Public Health;2024-04-25

5. Fixed-dose antiretroviral combinations in children living with human immunodeficiency virus type 1 (HIV-1): a systematic review;Journal of Chemotherapy;2023-12-28